Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells
Işıl Altıntaş(Genmab (Netherlands)), Robbert J. Kok(Utrecht University), Wim E. Hennink(Utrecht University), Raymond M. Schiffelers(University Medical Center Utrecht), M. Lacombe(Université du Québec à Rimouski), Roy van der Meel(Eindhoven University of Technology), Raimond Heukers(Utrecht University), Maryam Amidi(Merck Serono S.p.A. (Italy)), Paul M.P. van Bergen en Henegouwen(Utrecht University)
Cited by 115
Related Papers
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
The current landscape of nucleic acid therapeutics
|Nature Nanotechnology|2021|1.3k
Smart cancer nanomedicine
|Nature Nanotechnology|2019|1.2k
On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA
|ACS Nano|2018|638
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
|Nucleic Acid Therapeutics|2018|562